science wire

« BACK

Pharmacology



Results 351 - 400 of 1331.
« Previous 1 ... 4 5 6 7 8 9 10 11 12 ... 27 Next »


Health - Pharmacology - 30.04.2018
Novartis receives FDA approval of Tafinlar + Mekinist for adjuvant treatment of BRAF V600-mutant melanoma
Tafinlar + Mekinist is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection  

Pharmacology - Health - 30.04.2018
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week 48 Pr

Health - Pharmacology - 27.04.2018
CHMP recommends EU approval of Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
In the large phase III APHINITY study, the combination of Perjeta, Herceptin and chemotherapy significantly reduced the risk of invasive breast cancer recurrence or death by 19% compared to Herceptin

Pharmacology - Health - 17.04.2018
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
Company to invest more than USD 100 million to advance research and development of new antimalarials over the next five years   Commitment includes expanding access to pediatric antimalarials and imp

Pharmacology - Health - 17.04.2018
Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures
Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures The LIBERTY trial studie

Pharmacology - Health - 17.04.2018
FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors
Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine to show superior efficacy compared to prior fact

Health - Pharmacology - 16.04.2018
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes Heart failure (HF) patients with reduced

Health - Pharmacology - 07.04.2018
Sandoz outlines plans for next Healthcare Access Challenge (HACk), to support local digital innovation
Sandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcare Publication, which coincides with World Healt

Health - Pharmacology - 04.04.2018
Novartis announces JAMA Cardiology publication of data showing Entresto improves physical and social activity in HFrEF patients versus enalapril
Novartis announces JAMA Cardiology publication of data showing Entresto improves physical and social activity in HFrEF patients versus enalapril Post-hoc analysis of PARADIGM-HF published in JAMA Car

Health - Pharmacology - 04.04.2018
Enhanced therapeutic vaccine platform achieves two proof of concepts in veterinary medical use
Enhanced therapeutic vaccine platform achieves two proof of concepts in veterinary medical use
Chronical allergic diseases of dogs and horses can now be treated with an innovative vaccine. It was developed by an international research team led by he University of Bern and in cooperation with the University of Zurich, together with private enterprise companies. The findings obtained in horses and dogs could lead to similar herapeutic vaccines for humans.

Health - Pharmacology - 04.04.2018
Therapeutic vaccine platform achieves proof of concepts in veterinary medical use
Scientists from the Universities of Bern, Zurich and Oxford as well as the Latvian Biomedical Research & Study Centre led by Prof. Martin F. Bachmann (University Clinic of Rheumatology, Immunoloy and Allergology, University of Bern) have developed a new therapeutic vaccine technology based upon enhanced virus like nanoparticle conjugates.

Pharmacology - Health - 28.03.2018
Roche announces Japanese court ruled in favour of Chugai in Hemlibra patent litigation
Roche today announced that a Japanese court (Tokyo District Court) ruled in favour of Chugai Pharmaceutical Co.

Pharmacology - Health - 28.03.2018
Novartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVO
Novartis will present new data from the HAWK and HARRIER Phase III trials at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, Honolulu, April 29 - May 3.

Pharmacology - Health - 26.03.2018
Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel
Phase III IMpower150 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin pl

Pharmacology - Health - 23.03.2018
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients   Results demonstrate siponimod al

Health - Pharmacology - 22.03.2018
Novartis drug Tasigna approved by FDA to treat children with rare form of leukemia
Tasigna (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy   New indication approved under FDA Prior

Health - Pharmacology - 22.03.2018
North and South Cooperation to Combat Tuberculosis
North and South Cooperation to Combat Tuberculosis
More than 4,000 people worldwide die from tuberculosis every day. This means the disease tops the list of the most common causes of death that result from a single pathogen.

Health - Pharmacology - 21.03.2018

Pharmacology - Health - 20.03.2018
Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer
Phase III IMpower131 study showed Roche's TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with

Health - Pharmacology - 19.03.2018
LSD Blurs Boundaries between the experience of Self and Other
Virtually all mental health disorders come with difficulties in interpersonal relations that in the long run negatively affect the progression of the disease. The associated health an social restrictions can only be marginally improved by current forms of therapy. One of the reasons for this is that there has been very little research into the basic neurobiological principles and in particular the neurochemical mechanisms of these kinds of disorders.

Health - Pharmacology - 06.03.2018
Novartis’ Xolair recommended in new global chronic urticaria guideline
Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU) , is the only therapy recommended by the guideline for patients unresponsive to antihistamine

Pharmacology - Health - 27.02.2018
European Commission approves Roche’s Hemlibra for people with haemophilia A with inhibitors
European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors First new medicine in over 20 years to treat people with haemophilia A with inhibitors in Europe Hemlibra d

Health - Pharmacology - 27.02.2018
Lausanne-Villigen return
Nowhere in the world have so many ocular tumours been irradiated with protons as at the Paul Scherrer Institute PSI.

Health - Pharmacology - 22.02.2018
Treatment with Novartis’ Ultibro Breezhaler improved cardiac function in COPD patients with lung hyperinflation
Ultibro Breezhaler provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo     CLAIM is the first study to investigate the effect of dual bronchodilation on cardiac function   Data published in the Lancet Respiratory Medicine Basel, February 22, 2018 - Novartis today announced the publication of the CLAIM * study in the Lancet Respiratory Medicine, which demonstrated that trea

Health - Pharmacology - 16.02.2018
Novartis new Cosentyx data confirms robust efficacy and quality of life improvements in scalp psoriasis
Majority of patients with scalp psoriasis on Cosentyx (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life   Scalp psoriasis affects 60 million people worldwide - a difficult-to-treat form of psoriasis with a substantial impact on quality of life -   Cosentyx data presented at AAD adds to robust evidence demonstrating sustained efficacy in plaque, nail, palmoplantar and scalp psoriasis as well as psoriatic

Pharmacology - Health - 13.02.2018
Sandoz announces US FDA approval and launch of Glatopa 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
Sandoz announces US FDA approval and launch of Glatopa 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis Glatopa 40 mg/mL is a fully substitutable, AP-rated generic

Health - Pharmacology - 08.02.2018
Novartis receives FDA approval for Cosentyx label update to include moderate-to-severe scalp psoriasis
US label updated to include Cosentyx (secukinumab) data in moderate-to-severe scalp psoriasis - one of the difficult-to-treat types of psoriasis   Approximately half of all 125 million patients with

Pharmacology - Health - 06.02.2018
Phase III IMmotion151 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Phase III IMmotion151 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cance

Health - Pharmacology - 31.01.2018
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL Analysis of 75 patients with m

Pharmacology - Health - 26.01.2018
Advanced Accelerator Applications Receives FDA Approval for Lutathera for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Lutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT)   Advanced Accelerator Applications is a newly established subsidiary of Novartis   Lutathera expands Novartis' n

Health - Pharmacology - 26.01.2018

Pharmacology - Health - 26.01.2018
CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors
Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies across age groups With once-weekly subcutaneous (under the skin) administration, Hem

Pharmacology - Business / Economics - 24.01.2018
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
Full year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto , more than offset Gleevec/Glivec generic erosion: Cosentyx grew to USD 2.1 bi

Health - Pharmacology - 24.01.2018
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss Novartis enters into a licensing and supply agre

Pharmacology - Health - 22.01.2018
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments LIBERTY is the first mi

Health - Pharmacology - 17.01.2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Filing acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA-approved CAR-T therapy   EMA granted accelerate
« Previous 1 ... 4 5 6 7 8 9 10 11 12 ... 27 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |